AHL
RLAY icon

Abel Hall LLC’s Relay Therapeutics RLAY Stock Holding History

Abel Hall LLC’s Portfolio RLAY Stock Details RLAY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$181K Buy
18,237
+5,253
+40% +$47K 0.04% 635
2025
Q4 		$110K Buy
12,984
+1,809
+16% +$12.9K 0.03% 605
2025
Q3 		$58.3K Buy
+11,175
New +$42.6K 0.02% 296

Other funds holding RLAY

SIAU
SB Investment Advisers (UK) London, United Kingdom $7.73B AUM 2.35% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Abel Hall LLC's RLAY Position: Q1 2026 in Review

Abel Hall LLC increased its Relay Therapeutics (RLAY) stake by 40% in Q1 2026, buying an estimated $47K and bringing the position to 18,237 shares worth $181K. The position accounts for 0.04% of the portfolio, ranked #635.

Abel Hall LLC first reported a position in RLAY in Q3 2025 and has held it in 3 quarters since. 242 funds tracked by Wall St. Rank hold RLAY as of Q1 2026.

  • Abel Hall LLC held 18,237 shares of Relay Therapeutics worth $181K as of Q1 2026.
  • Abel Hall LLC bought 5,253 Relay Therapeutics shares in Q1 2026, an estimated $47K.
  • Relay Therapeutics made up 0.04% of Abel Hall LLC's portfolio in Q1 2026, its #635 holding.
  • Abel Hall LLC first reported a position in Relay Therapeutics in Q3 2025 and has held it in 3 quarters since.
  • 242 funds tracked by Wall St. Rank held Relay Therapeutics as of Q1 2026.

Based on Abel Hall LLC's 13F filing for Q1 2026, filed 28 Apr 2026.